MTC B7
Alternative Names: MTC-B7Latest Information Update: 22 Nov 2022
Price :
$50 *
At a glance
- Originator Biotts
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 15 Sep 2022 Preclinical trials in Breast cancer in Poland (Transdermal) (Biotts pipeline, September 2022)
- 15 Sep 2022 Biotts plans for a phase I clinical trial in Breast cancer (Transdermal) (Biotts pipeline, September 2022)
- 01 Sep 2020 MTC B7 is available for licensing as of 01 Sep 2020. https://biotts.com/en/our-products/#leki 3707319